Total Payments
$1.0M
2024 Payments
$12,395
Companies
7
Transactions
302
Medicare Patients
32,358
Medicare Billing
$674,826
Payment Breakdown by Category
Consulting$959,910 (95.2%)
Research$48,780 (4.8%)
Food & Beverage$23.08 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $959,910 | 240 | 95.2% |
| Unspecified | $48,780 | 61 | 4.8% |
| Food and Beverage | $23.08 | 1 | 0.0% |
Payments by Type
General
$959,933
241 transactions
Research
$48,780
61 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $805,730 | 207 | $0 (2021) |
| PFIZER INC. | $144,860 | 23 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $48,780 | 61 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $7,710 | 6 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,050 | 1 | $0 (2023) |
| Astellas Pharma Inc | $560.00 | 3 | $0 (2020) |
| GE Healthcare | $23.08 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,395 | 12 | Regeneron Pharmaceuticals, Inc. ($12,395) |
| 2023 | $24,745 | 13 | Regeneron Pharmaceuticals, Inc. ($15,985) |
| 2022 | $920.00 | 3 | Regeneron Pharmaceuticals, Inc. ($920.00) |
| 2021 | $77,310 | 37 | Merck Sharp & Dohme Corporation ($73,980) |
| 2020 | $191,665 | 42 | Merck Sharp & Dohme Corporation ($182,545) |
| 2019 | $186,798 | 73 | Merck Sharp & Dohme Corporation ($132,185) |
| 2018 | $334,545 | 88 | Merck Sharp & Dohme Corporation ($236,685) |
| 2017 | $180,335 | 34 | Merck Sharp & Dohme Corporation ($180,335) |
All Payment Transactions
302 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $165.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 11/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $220.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 10/08/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $440.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 09/17/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,265.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 08/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $935.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 07/09/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $385.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 06/11/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $165.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 05/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $55.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 04/16/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $110.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 03/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $110.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 02/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $370.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 01/09/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $8,175.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 12/26/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $6,405.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 12/12/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $7,920.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 12/01/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $40.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 11/01/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $940.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 10/02/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 09/05/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $220.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 09/01/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,835.00 | General |
| 08/15/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $460.00 | Research |
| Study: A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 07/03/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 07/03/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 07/03/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES | Regeneron Pharmaceuticals, Inc. | $37,020 | 38 |
| A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer | Regeneron Pharmaceuticals, Inc. | $6,160 | 8 |
| A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $3,700 | 14 |
| A Phase 1 Study to Investigate the Safety and Pharmacokinetics of REGN2810 Anti-PD-1 in Japanese Patients With Advanced Malignancies | Regeneron Pharmaceuticals, Inc. | $1,900 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 59 | 11,449 | 15,066 | $1.7M | $246,236 |
| 2022 | 53 | 8,625 | 12,015 | $1.1M | $173,457 |
| 2021 | 46 | 6,881 | 8,811 | $875,417 | $141,804 |
| 2020 | 41 | 5,403 | 6,612 | $678,728 | $113,329 |
Total Patients
32,358
Total Services
42,504
Medicare Billing
$674,826
Procedure Codes
284
All Medicare Procedures & Services
284 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 1,818 | 2,767 | $116,214 | $21,747 | 18.7% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 138 | 306 | $141,240 | $15,105 | 10.7% |
| 73564 | X-ray of knee, 4 or more views | Office | 2023 | 403 | 478 | $57,553 | $13,537 | 23.5% |
| 73721 | Mri scan of leg joint without contrast | Office | 2023 | 68 | 73 | $108,535 | $13,013 | 12.0% |
| 73562 | X-ray of knee, 3 views | Office | 2023 | 365 | 473 | $54,930 | $12,443 | 22.7% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 316 | 385 | $59,070 | $11,529 | 19.5% |
| 73502 | X-ray of hip, 2-3 views | Office | 2023 | 348 | 356 | $71,106 | $10,419 | 14.7% |
| 73030 | X-ray of shoulder, minimum of 2 views | Office | 2023 | 452 | 514 | $64,585 | $10,214 | 15.8% |
| 73221 | Mri scan of arm joint without contrast | Office | 2023 | 51 | 53 | $78,745 | $10,119 | 12.9% |
| 73630 | X-ray of foot, minimum of 3 views | Office | 2023 | 343 | 402 | $50,696 | $7,913 | 15.6% |
| 73110 | X-ray of wrist, minimum of 3 views | Office | 2023 | 239 | 281 | $47,484 | $7,898 | 16.6% |
| 73721 | Mri scan of leg joint without contrast | Facility | 2023 | 103 | 106 | $40,500 | $6,132 | 15.1% |
| 72192 | Ct scan of pelvis without contrast | Facility | 2023 | 126 | 128 | $33,024 | $5,979 | 18.1% |
| 73502 | X-ray of hip, 2-3 views | Facility | 2023 | 499 | 577 | $63,046 | $5,247 | 8.3% |
| 73700 | Ct scan of leg without contrast | Facility | 2023 | 101 | 110 | $34,928 | $4,752 | 13.6% |
| 72100 | X-ray of lower and sacral spine, 2-3 views | Office | 2023 | 208 | 208 | $24,709 | $4,543 | 18.4% |
| 73718 | Mri scan of leg without contrast | Office | 2023 | 18 | 18 | $26,640 | $4,081 | 15.3% |
| 73030 | X-ray of shoulder, minimum of 2 views | Facility | 2023 | 390 | 429 | $27,601 | $3,626 | 13.1% |
| 73610 | X-ray of ankle, minimum of 3 views | Office | 2023 | 162 | 188 | $27,197 | $3,452 | 12.7% |
| 73562 | X-ray of knee, 3 views | Facility | 2023 | 356 | 401 | $26,972 | $3,439 | 12.8% |
| 73564 | X-ray of knee, 4 or more views | Facility | 2023 | 286 | 313 | $23,246 | $3,375 | 14.5% |
| 73720 | Mri scan of leg before and after contrast | Facility | 2023 | 29 | 36 | $22,140 | $3,281 | 14.8% |
| 73630 | X-ray of foot, minimum of 3 views | Facility | 2023 | 361 | 422 | $25,519 | $3,138 | 12.3% |
| 73221 | Mri scan of arm joint without contrast | Facility | 2023 | 51 | 53 | $20,010 | $3,096 | 15.5% |
| 73200 | Ct scan of arm without contrast | Facility | 2023 | 70 | 72 | $20,580 | $3,015 | 14.7% |
About Dr. Kevin Baker, MD
Dr. Kevin Baker, MD is a Diagnostic Radiology healthcare provider based in Stony Brook, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2010. The National Provider Identifier (NPI) number assigned to this provider is 1053639484.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Baker, MD has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $12,395 received in 2024. These payments were reported across 302 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($959,910).
As a Medicare-enrolled provider, Baker has provided services to 32,358 Medicare beneficiaries, totaling 42,504 services with total Medicare billing of $674,826. Data is available for 4 years (2020–2023), covering 284 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Other Specialties Student in an Organized Health Care Education/Training Program, Diagnostic Radiology
- Location Stony Brook, NY
- Active Since 05/10/2010
- Last Updated 01/11/2022
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1053639484
Products in Payments
- KEYTRUDA (Biological) $805,730
- BAVENCIO (Drug) $144,860
- LIBTAYO (Biological) $47,180
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $1,600
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Stony Brook
Michael Reiter, D.o, D.O
Diagnostic Radiology — Payments: $243,806
Diagnostic Radiology $243,806
Dr. Steven West, M.d, M.D
Diagnostic Radiology — Payments: $234,190
Diagnostic Radiology $234,190
Dr. Lev Bangiyev, Do, DO
Diagnostic Radiology — Payments: $129,200
Diagnostic Radiology $129,200
Annapurneswara Chimpiri, Md, MD
Diagnostic Radiology — Payments: $30,887
Diagnostic Radiology $30,887
Charles Lugo, M.d, M.D
Diagnostic Radiology — Payments: $22,881
Diagnostic Radiology $22,881
Dr. Vladimir Sheynzon, Md, MD
Diagnostic Radiology — Payments: $11,777
Diagnostic Radiology $11,777